JP2013535217A - 滅菌されたヒト細胞懸濁液の製造法 - Google Patents
滅菌されたヒト細胞懸濁液の製造法 Download PDFInfo
- Publication number
- JP2013535217A JP2013535217A JP2013523518A JP2013523518A JP2013535217A JP 2013535217 A JP2013535217 A JP 2013535217A JP 2013523518 A JP2013523518 A JP 2013523518A JP 2013523518 A JP2013523518 A JP 2013523518A JP 2013535217 A JP2013535217 A JP 2013535217A
- Authority
- JP
- Japan
- Prior art keywords
- perfusion
- tissue
- buffer
- antibiotic
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 8
- 239000006285 cell suspension Substances 0.000 title claims description 22
- 210000005260 human cell Anatomy 0.000 title description 2
- 238000002360 preparation method Methods 0.000 claims abstract description 37
- 238000000034 method Methods 0.000 claims abstract description 31
- 230000003115 biocidal effect Effects 0.000 claims description 68
- 210000001519 tissue Anatomy 0.000 claims description 66
- 230000010412 perfusion Effects 0.000 claims description 65
- 239000000203 mixture Substances 0.000 claims description 44
- 239000000872 buffer Substances 0.000 claims description 35
- 102000029816 Collagenase Human genes 0.000 claims description 27
- 108060005980 Collagenase Proteins 0.000 claims description 27
- 102000004190 Enzymes Human genes 0.000 claims description 27
- 108090000790 Enzymes Proteins 0.000 claims description 27
- 229940088598 enzyme Drugs 0.000 claims description 27
- 238000011282 treatment Methods 0.000 claims description 27
- 229960002424 collagenase Drugs 0.000 claims description 26
- 102000035195 Peptidases Human genes 0.000 claims description 23
- 108091005804 Peptidases Proteins 0.000 claims description 23
- 239000003242 anti bacterial agent Substances 0.000 claims description 23
- 239000007995 HEPES buffer Substances 0.000 claims description 18
- 235000019833 protease Nutrition 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 13
- 229940088710 antibiotic agent Drugs 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 11
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 8
- 230000002255 enzymatic effect Effects 0.000 claims description 7
- 210000005228 liver tissue Anatomy 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 5
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 239000011534 wash buffer Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 56
- 210000000056 organ Anatomy 0.000 description 29
- 210000004185 liver Anatomy 0.000 description 16
- 230000001954 sterilising effect Effects 0.000 description 14
- 210000003494 hepatocyte Anatomy 0.000 description 12
- 244000005700 microbiome Species 0.000 description 12
- 239000000463 material Substances 0.000 description 11
- 238000004659 sterilization and disinfection Methods 0.000 description 11
- 239000004365 Protease Substances 0.000 description 9
- 238000005202 decontamination Methods 0.000 description 9
- 235000019419 proteases Nutrition 0.000 description 9
- 239000006163 transport media Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 8
- 238000002054 transplantation Methods 0.000 description 8
- 230000012010 growth Effects 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 238000013190 sterility testing Methods 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 5
- 238000011109 contamination Methods 0.000 description 5
- 238000005138 cryopreservation Methods 0.000 description 5
- 230000003588 decontaminative effect Effects 0.000 description 5
- 208000000509 infertility Diseases 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 230000002411 adverse Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000036512 infertility Effects 0.000 description 4
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 101000693530 Staphylococcus aureus Staphylokinase Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229940126575 aminoglycoside Drugs 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000021028 berry Nutrition 0.000 description 2
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000003641 microbiacidal effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 239000002132 β-lactam antibiotic Substances 0.000 description 2
- 229940124586 β-lactam antibiotics Drugs 0.000 description 2
- GXVUZYLYWKWJIM-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanamine Chemical compound NCCOCCN GXVUZYLYWKWJIM-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 241000588626 Acinetobacter baumannii Species 0.000 description 1
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 206010000804 Acute hepatic failure Diseases 0.000 description 1
- 108090000145 Bacillolysin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000010334 End Stage Liver Disease Diseases 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000035092 Neutral proteases Human genes 0.000 description 1
- 108091005507 Neutral proteases Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical group NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 208000011444 chronic liver failure Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/067—Hepatocytes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0215—Disinfecting agents, e.g. antimicrobials for preserving living parts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Dentistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Materials For Medical Uses (AREA)
Abstract
【選択図】 なし
Description
A.実施
肝臓に由来する滅菌された肝細胞懸濁液を製造するために、以下の抗生物質組成物を製造した:
抗生物質は、記載されるすべての灌流用緩衝液に以下の濃度で加えた:
1.EDTA含有リン酸-HEPES-緩衝液5L;灌流10分;20〜40℃;
2.リン酸-HEPES-緩衝液5L;灌流10分;25〜40℃;
3.コラゲナーゼ/プロテアーゼ含有リン酸-HEPES-緩衝液3L;灌流24分;25〜40℃
コラゲナーゼ/プロテアーゼ濃度:2000ヴュンシュユニットのコラゲナーゼI及び400〜2500ユニットのプロテアーゼ(クロストリジオペプチダーゼI)からなる組合せ。
輸送培地中には、以下の微生物が検出された:エンテロバクター・クロアカ(Enterobacter cloacae)、アシネトバクター・バウマニ(Acinetobacter baumannii)、ただし、微生物的な成長が認められるまでの、自動インキュベーションの時間、いわゆる「陽性となるまでの時間(Time to positivity)」は、1.67時間であった。
A.実施
全臓器移植には適さない複数ドナー肝臓をまず表面的に、抗生物質濃度が2倍のリン酸-HEPES-緩衝液5Lを用いて、室温におき8分洗浄し、続いて二ステップにおき抗生物質含有緩衝液を用いて、さらなる一ステップにおきコラゲナーゼを含み抗生物質を含まない緩衝液を用いて以下の体積、pH7.25〜7.45で灌流した:
1.EDTA含有リン酸-HEPES-緩衝液10L;灌流68分;20〜40℃;
2.リン酸-HEPES-緩衝液5L;灌流10分;25〜40℃;
3.コラゲナーゼ/プロテアーゼを含み抗生物質を含まないリン酸-HEPES-緩衝液3L;灌流24分;25〜40℃
コラゲナーゼ/プロテアーゼ濃度:2000ヴュンシュユニットのコラゲナーゼI及び400〜2500ユニットのプロテアーゼ(クロストリジオペプチダーゼI)からなる組合せ。
輸送培地中には、黄色ブドウ球菌(Staphylococcus Aureus)を検出することができた。微生物的な成長が認められるまでの、自動インキュベーションの時間、いわゆる「陽性となるまでの時間(Time to positivity)」は、3.85時間であった。
Claims (12)
- 以下のステップ:
a)液状抗生物質組成物による、哺乳動物に由来する組織の灌流、
b)単一細胞懸濁液を獲得するための、組織の酵素処理の実施、及び
c)滅菌された調製品の獲得
を含む、哺乳動物の組織に由来する滅菌された調製品の製造法。 - 組織が肝組織である、請求項1に記載の方法。
- ステップb)に基づく酵素処理がステップa)と同時に行われる、請求項1又は2に記載の方法。
- ステップb)に基づく酵素処理がステップa)に続いて行われる、請求項1又は2に記載の方法。
- 酵素処理がコラゲナーゼ処理及び/又はプロテイナーゼ処理である、請求項1〜4のいずれか一項に記載の方法。
- ステップa)での灌流時間が30〜120分であり、灌流の間に温度が高められる、請求項1〜5のいずれか一項に記載の方法。
- 液状抗生物質組成物が少なくとも一つのコラゲナーゼ及び/又は少なくとも一つのプロテイナーゼを含有する、請求項1〜6のいずれか一項に記載の方法。
- 液状抗生物質組成物が、少なくとも一つの灌流用緩衝液中に存在し、少なくとも一つの抗生物質を含む、請求項1〜7のいずれか一項に記載の方法。
- 液状抗生物質組成物が、少なくとも二つの灌流用緩衝液中、詳しくは少なくとも一つのEGTA又はEDTA含有リン酸-HEPES-緩衝液、及び少なくとも一つのリン酸-HEPES-緩衝液中に存在する、請求項1〜8のいずれか一項に記載の方法。
- ステップa)に先立ち、液状抗生物質組成物により組織の表面が洗浄される、請求項1〜9のいずれか一項に記載の方法。
- ステップb)に続いて少なくとも一回の、抗生物質を含まない洗浄用緩衝液による洗浄ステップが実施される、請求項1〜10のいずれか一項に記載の方法。
- 請求項1〜11のいずれか一項に記載の方法で製造された、滅菌された哺乳動物細胞調製品。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102010034330A DE102010034330B4 (de) | 2010-08-14 | 2010-08-14 | Verfahren zur Herstellung desinfizierter humaner Zellsuspensionen |
DE102010034330.7 | 2010-08-14 | ||
PCT/EP2011/003838 WO2012022429A1 (de) | 2010-08-14 | 2011-07-30 | Verfahren zur herstellung desinfizierter humaner zellsuspensionen |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013535217A true JP2013535217A (ja) | 2013-09-12 |
JP5859532B2 JP5859532B2 (ja) | 2016-02-10 |
Family
ID=44509172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013523518A Active JP5859532B2 (ja) | 2010-08-14 | 2011-07-30 | 滅菌されたヒト細胞懸濁液の製造法 |
Country Status (18)
Country | Link |
---|---|
US (2) | US8999710B2 (ja) |
EP (1) | EP2603074B1 (ja) |
JP (1) | JP5859532B2 (ja) |
KR (1) | KR101822961B1 (ja) |
CN (1) | CN103124493A (ja) |
AR (1) | AR082668A1 (ja) |
AU (1) | AU2011291058B2 (ja) |
BR (1) | BR112013003484B1 (ja) |
CA (1) | CA2807890C (ja) |
DE (1) | DE102010034330B4 (ja) |
DK (1) | DK2603074T3 (ja) |
ES (1) | ES2571241T3 (ja) |
HK (1) | HK1181258A1 (ja) |
IL (1) | IL224648A (ja) |
PL (1) | PL2603074T3 (ja) |
RU (1) | RU2563806C2 (ja) |
WO (1) | WO2012022429A1 (ja) |
ZA (1) | ZA201300532B (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103525756B (zh) * | 2013-10-23 | 2015-04-08 | 南京农业大学 | 一种原代鸡肝细胞的分离培养方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002529201A (ja) * | 1998-11-13 | 2002-09-10 | リジェネレーション テクノロジーズ インク. | 組織をプールする方法 |
JP2006506971A (ja) * | 2002-07-19 | 2006-03-02 | ヴェスタ セラピューティクス,インコーポレーテッド | 肝性幹/前駆細胞を含む生存能のあるヒト肝臓細胞を得る方法 |
JP2007519465A (ja) * | 2004-01-27 | 2007-07-19 | ラモト アット テル − アビブ ユニバーシティー リミテッド | 皮膚病変部の酵素的壊死組織除去用装置および方法 |
WO2010021714A2 (en) * | 2008-08-20 | 2010-02-25 | Anthrogenesis Corporation | Improved cell composition and methods of making the same |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4695536A (en) | 1984-01-10 | 1987-09-22 | Lindstrom Richard L | Corneal storage system |
SU1578192A1 (ru) * | 1988-04-26 | 1990-07-15 | Институт проблем онкологии им.Р.Е.Кавецкого | Способ выращивани клеток печени |
AU1412492A (en) | 1991-01-24 | 1992-08-27 | Cryolife, Inc. | Tissue cryopreservation method |
US5741782A (en) | 1996-03-29 | 1998-04-21 | Cryolife, Inc. | Antibiotic cocktail and method of use |
WO2002042431A2 (en) * | 2000-11-22 | 2002-05-30 | Gwathmey, Inc. | Isolation procedure and optimized media solution to enhance long-term survival of cells |
US20030021775A1 (en) * | 2001-07-27 | 2003-01-30 | Ramot University Authority For Applied Research & Industrial Development Ltd. | Device for and method of controlled enzymatic removal and retrieval of tissue |
CN1746297A (zh) * | 2004-09-09 | 2006-03-15 | 中国人民解放军军事医学科学院基础医学研究所 | 胎盘来源间充质干细胞及其制备 |
US9598669B2 (en) * | 2005-12-29 | 2017-03-21 | Anthrogenesis Corporation | Composition for collecting placental stem cells and methods of using the composition |
-
2010
- 2010-08-14 DE DE102010034330A patent/DE102010034330B4/de not_active Expired - Fee Related
-
2011
- 2011-07-30 CN CN2011800382034A patent/CN103124493A/zh active Pending
- 2011-07-30 DK DK11748265.3T patent/DK2603074T3/en active
- 2011-07-30 US US13/816,909 patent/US8999710B2/en active Active
- 2011-07-30 KR KR1020137002618A patent/KR101822961B1/ko active IP Right Grant
- 2011-07-30 WO PCT/EP2011/003838 patent/WO2012022429A1/de active Application Filing
- 2011-07-30 CA CA2807890A patent/CA2807890C/en not_active Expired - Fee Related
- 2011-07-30 EP EP11748265.3A patent/EP2603074B1/de active Active
- 2011-07-30 RU RU2013111300/10A patent/RU2563806C2/ru active
- 2011-07-30 PL PL11748265T patent/PL2603074T3/pl unknown
- 2011-07-30 JP JP2013523518A patent/JP5859532B2/ja active Active
- 2011-07-30 ES ES11748265T patent/ES2571241T3/es active Active
- 2011-07-30 BR BR112013003484-0A patent/BR112013003484B1/pt not_active IP Right Cessation
- 2011-07-30 AU AU2011291058A patent/AU2011291058B2/en not_active Ceased
- 2011-08-12 AR ARP110102934A patent/AR082668A1/es unknown
-
2013
- 2013-01-21 ZA ZA2013/00532A patent/ZA201300532B/en unknown
- 2013-02-10 IL IL224648A patent/IL224648A/en active IP Right Grant
- 2013-07-29 HK HK13108828.6A patent/HK1181258A1/zh not_active IP Right Cessation
-
2014
- 2014-11-12 US US14/539,158 patent/US10017742B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002529201A (ja) * | 1998-11-13 | 2002-09-10 | リジェネレーション テクノロジーズ インク. | 組織をプールする方法 |
JP2006506971A (ja) * | 2002-07-19 | 2006-03-02 | ヴェスタ セラピューティクス,インコーポレーテッド | 肝性幹/前駆細胞を含む生存能のあるヒト肝臓細胞を得る方法 |
JP2007519465A (ja) * | 2004-01-27 | 2007-07-19 | ラモト アット テル − アビブ ユニバーシティー リミテッド | 皮膚病変部の酵素的壊死組織除去用装置および方法 |
WO2010021714A2 (en) * | 2008-08-20 | 2010-02-25 | Anthrogenesis Corporation | Improved cell composition and methods of making the same |
Non-Patent Citations (3)
Title |
---|
ALEXANDROVA KRASSIMIRA ET AL: "LARGE-SCALE ISOLATION OF HUMAN HEPATOCYTES FOR THERAPEUTIC APPLICATION", CELL TRANSPLANTATION, vol. 14, JPN5013009451, 2005, US, pages 845 - 853, XP009154317, ISSN: 0003203782, DOI: 10.3727/000000005783982530 * |
GERLACH JOERG C ET AL: "COMPARISON OF FOUR METHODS FOR MASS HEPATOCYTE ISOLATION FROM PIG AND HUMAN LIVERS", TRANSPLANTATION, vol. 57, no. 9, JPN5013009450, May 1994 (1994-05-01), US, pages 1318 - 1322, XP009154462, ISSN: 0003073035, DOI: 10.1097/00007890-199405150-00005 * |
MITRY RAGAI R ET AL: "HUMAN HEPATOCYTE ISOLATION AND RELATIONSHIP OF CELL VIABILITY TO EARLY GRAFT FUNCTION", CELL TRANSPLANTATION, vol. 12, no. 1, JPN5013009452, 2003, US, pages 69 - 74, XP009154318, ISSN: 0003203783, DOI: 10.3727/000000003783985197 * |
Also Published As
Publication number | Publication date |
---|---|
CN103124493A (zh) | 2013-05-29 |
ZA201300532B (en) | 2014-03-26 |
DK2603074T3 (en) | 2016-05-23 |
DE102010034330B4 (de) | 2013-10-31 |
WO2012022429A1 (de) | 2012-02-23 |
JP5859532B2 (ja) | 2016-02-10 |
EP2603074B1 (de) | 2016-02-24 |
ES2571241T3 (es) | 2016-05-24 |
CA2807890C (en) | 2019-06-25 |
CA2807890A1 (en) | 2012-02-23 |
AU2011291058A1 (en) | 2013-02-07 |
BR112013003484B1 (pt) | 2019-04-24 |
PL2603074T3 (pl) | 2016-08-31 |
AU2011291058B2 (en) | 2015-10-15 |
IL224648A (en) | 2016-10-31 |
KR101822961B1 (ko) | 2018-01-29 |
US10017742B2 (en) | 2018-07-10 |
KR20130098990A (ko) | 2013-09-05 |
AR082668A1 (es) | 2012-12-26 |
EP2603074A1 (de) | 2013-06-19 |
RU2563806C2 (ru) | 2015-09-20 |
US20130143324A1 (en) | 2013-06-06 |
BR112013003484A2 (pt) | 2016-09-13 |
HK1181258A1 (zh) | 2013-11-08 |
US8999710B2 (en) | 2015-04-07 |
US20150072428A1 (en) | 2015-03-12 |
RU2013111300A (ru) | 2014-09-20 |
DE102010034330A1 (de) | 2012-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101679889B1 (ko) | 세포, 인공세포 구조물 또는 3차원 복합 조직 어셈블리의 냉동보존 방법 | |
US8198085B2 (en) | Somatic cells for use in cell therapy | |
US6531310B1 (en) | Use of microorganisms for processing bioprosthetic tissue | |
JP2000507953A (ja) | 抗生物質カクテル及び使用の方法 | |
CN107006452A (zh) | 一种人脐带间充质干细胞源外泌体冻干保存方法及其应用 | |
CN109182129B (zh) | 一种细菌保护剂及其应用 | |
JP5859532B2 (ja) | 滅菌されたヒト細胞懸濁液の製造法 | |
Silvestre et al. | Vitrification and rapid freezing of rabbit fetal tissues and skin samples from rabbits and pigs | |
JP3509148B2 (ja) | 凍害保護剤および凍結保存方法 | |
Khalid et al. | Comparison of Gentamicin and Ciprofloxacin in Dromedary Camels” Semen Extender | |
CN107254446A (zh) | 一种人原代肿瘤细胞的分离制备方法 | |
RU2499611C1 (ru) | Способ повышения биосовместимости трансплантатов клапанов сердца и сосудов | |
JP2008104407A (ja) | 細胞保存方法 | |
RU2510416C1 (ru) | Питательная среда для выделения лактобактерий | |
CZ2017396A3 (cs) | Prostředek pro uchování lidských nebo zvířecích buněk při velmi nízkých teplotách a jeho použití | |
EP1391151A1 (en) | Thinner for conservation of sperm | |
WO2018147457A1 (ja) | ヒト幹細胞の保存液、ヒト幹細胞懸濁液およびヒト幹細胞の保存方法 | |
US20100233669A1 (en) | Bioburden-reducing antibiotic composition and method of use | |
UA34560A (uk) | Спосіб культивування збудників туберкульозу та атипових мікобактерій |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20130909 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130909 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140227 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150519 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150722 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20151201 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20151216 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5859532 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |